|
|
Volumn 9, Issue 10, 2010, Pages 749-750
|
|
Alzheimer's failure raises questions about disease-modifying strategies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN;
GAMMA SECRETASE;
NOTCH1 RECEPTOR;
PLACEBO;
SEMAGACESTAT;
ALANINE;
AZEPINE DERIVATIVE;
N2-((2S)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYETHANOYL)-N1-((7S)-5-METHYL-6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-L-ALANINAMIDE;
SECRETASE;
ALZHEIMER DISEASE;
CANCER RISK;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG TARGETING;
DRUG TREATMENT FAILURE;
ENZYME INHIBITION;
ENZYME SPECIFICITY;
HUMAN;
MILD COGNITIVE IMPAIRMENT;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN CLEAVAGE;
SHORT SURVEY;
SKIN CANCER;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
CHEMICALLY INDUCED;
DRUG INDUSTRY;
ENZYMOLOGY;
PHASE 3 CLINICAL TRIAL (TOPIC);
SKIN TUMOR;
TREATMENT FAILURE;
TRENDS;
ALANINE;
ALZHEIMER DISEASE;
AMYLOID PRECURSOR PROTEIN SECRETASES;
AZEPINES;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG INDUSTRY;
HUMANS;
SKIN NEOPLASMS;
TREATMENT FAILURE;
|
|
EID: 77957361080
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3288 Document Type: Short Survey |
|
Times cited : (152)
|
|
References (0)
|
